SS
INBX icon

Sunbelt Securities’s Inhibrx INBX Stock Holding History

Sunbelt Securities’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$538 Hold
8
– – ﹤0.01% 2269
2025
Q4 		$632 Hold
8
– – ﹤0.01% 2183
2025
Q3 		$269 Buy
+8
New +$197 ﹤0.01% 2366

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sunbelt Securities's INBX Position: Q1 2026 in Review

Sunbelt Securities held its Inhibrx (INBX) position steady in Q1 2026 at 8 shares worth $538. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Sunbelt Securities first reported a position in INBX in Q3 2025 and has held it in 3 quarters since. The position peaked at $632 in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Sunbelt Securities held 8 shares of Inhibrx worth $538 as of Q1 2026.
  • Sunbelt Securities left its Inhibrx share count unchanged in Q1 2026.
  • Inhibrx made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2269 holding.
  • Sunbelt Securities first reported a position in Inhibrx in Q3 2025 and has held it in 3 quarters since.
  • Sunbelt Securities's Inhibrx position peaked at $632 in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.